Core Viewpoint - Ascentage Pharma Group International is actively participating in investor conferences in September 2025 to discuss its advancements in biopharmaceuticals, particularly in cancer therapies [1][8]. Company Overview - Ascentage Pharma is a global, commercial stage, integrated biopharmaceutical company focused on discovering, developing, and commercializing novel therapies for unmet medical needs in cancer [3][4]. - The company has developed a rich pipeline of innovative drug products, including inhibitors targeting key proteins in the apoptotic pathway and next-generation kinase inhibitors [3][4]. Product Pipeline - The first approved product, Olverembatinib, is a third-generation BCR-ABL1 inhibitor for treating chronic myeloid leukemia (CML) with T315I mutations and is included in China's National Reimbursement Drug List [4]. - Olverembatinib is currently undergoing registrational Phase III trials, including POLARIS-2 for CML and POLARIS-1 and POLARIS-3 for other specific patient groups [4]. - The second approved product, Lisaftoclax, is a Bcl-2 inhibitor for various hematologic malignancies and has been approved for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients who have received prior systemic therapy [5]. - Lisaftoclax is involved in four global registrational Phase III trials, including studies in combination with BTK inhibitors and for newly diagnosed patients [5]. Research and Development - Ascentage Pharma has established a robust R&D capability and holds a portfolio of global intellectual property rights [6]. - The company has formed partnerships with leading biotechnology and pharmaceutical companies, including Takeda, AstraZeneca, Merck, and Pfizer, as well as collaborations with prominent research institutions [6].
Ascentage Pharma to Participate in Three Upcoming Investor Conferences in September 2025